Table 2.

Prognostic factors in hypocellular MDS (study group, n=169)

Parameters	Category	No.	Estimated survival			p-value
			Median (months)	2-year, %	3-year, %
Age, years	< 60	42	22.1	47	40
	60–64	35	16.9	37	19	0.21750
	≥ 65	92	15.7	34	15
Hemoglobin, g/dl	< 10	91	11	25	12
	10–11.9	59	16	44	26	0.00001
	≥ 12	19	47.9	85	68
Platelet, ×109/l	< 50	76	11	31	19
	50–99	42	21	44	25	0.02598
	≥100	51	27.8	64	31
Serum albumin, g/dl	< 4	81	12.1	25	14
	≥ 4	86	25	52	34	0.00859
Serum LDH, IU/l	≤ 600	104	22	45	28
	> 600	63	9.3	26	14	0.00031
Bone marrow cellularity	≤ 10%	52	15.7	33	24
	11–15%	48	20.3	49	39	0.04725
	≥ 15%	69	15.8	35	12
Bone marrow blast	< 5%	65	27.5	57	36
	5–19%	104	13	28	16	0.00311
Performance status	0–1	151	17.6	41	25
	≥ 2	18	7.4	19	6	0.02513
Therapy-related	No	124	20.3	43	27
	Yes	45	10.2	20	8	0.00983
Prior transfusion	No	80	26.7	53	33
	Yes	89	13.8	26	14	0.00706
β-2 microglobulin, mg/l	< 2	43	27.5	56	38
	2–3.9	61	19.4	38	23	0.00803
	≥ 4	19	10.2	12	0
Cytogenetics	Good	86	22.4	43	28
	Intermediate	22	19.1	58	35	0.00008
	Poor	61	7.4	23	11
Number of cytopenias	0/1	48	26.7	56	21
	2/3	121	12.7	30	23	0.00049
IPSS risk score	Low	19	27.7	77	38
	Int-1	49	22.1	47	31	0.00011
	Int-2	76	15.7	35	20
	High	25	6.9	8	8